SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

REVTORPYK

CELC·Celcuity Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
Why 4/10
REVTORPYK is already FDA-approved and commercially available, so the primary binary catalyst has passed. The next hard catalyst is the sNDA decision for the PIK3CA mutant label expansion, but no PDUFA date has been confirmed, so it is not a dated near-term binary. As an approved, launching product at a single-product company, the impact score is 4.
Actionable Insight MIXED

Watch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.

Price Chart

Loading chart...

Executive Summary

REVTORPYK (gedatolisib) is Celcuity Inc.'s first and only FDA-approved drug, cleared on July 14, 2026 for HR+/HER2-, PIK3CA wild-type advanced breast cancer. It is a kinase inhibitor that blocks PI3K and mTOR pathways. The drug became commercially available on September 30, 2026, and early launch metrics from the Q3 2026 earnings call showed strong account adoption (78% of top 36 strategic accounts ordering) and broad insurance coverage (91% of covered lives). A supplemental NDA for the larger PIK3CA mutant patient population was submitted in August 2026, which could roughly double the addressable market. The stock has fallen from ~$103 pre-approval to $66.79, reflecting a 'sell the news' pattern and investor concerns about the costly launch phase with no product revenue yet. Analyst consensus remains strongly bullish with a mean $151.25 price target.

How It Works

REVTORPYK is a kinase inhibitor that blocks multiple signaling pathways (class I PI3K isoforms and mTOR complexes) that cancer cells use to grow and survive. It is taken as an intravenous infusion and is designed to shut down these growth signals more broadly than existing targeted therapies.

Trial Status

REVTORPYK was approved by the FDA on July 14, 2026 based on the Phase 3 VIKTORIA-1 trial (NCT05501886, n=701) in HR+/HER2-, PIK3CA wild-type advanced breast cancer. The trial is now active but not recruiting, with primary completion estimated June 2026. Updated results from the PIK3CA mutant cohort were presented at ESMO 2026, showing median progression-free survival of 21.5 months with the gedatolisib triplet versus 9.1 months with alpelisib plus fulvestrant in patients without liver metastases.

The Two-Sided Case

▲ Bull Case5
First-in-class and only FDA-approved therapy that inhibits all class I PI3K isoforms and mTOR complexes, with a broad mechanism that may differentiate it from competitors like alpelisib
Strong early launch indicators: 78% of top 36 strategic accounts placed orders, 91% of US commercial and Medicare lives covered by health plans, per Q3 2026 earnings
Massive institutional accumulation in Q2 and Q3 2026, with major funds like FMR LLC (Fidelity), Bank of America, Wellington, and Point72 doubling or initiating positions
Analyst consensus is overwhelmingly bullish: 18 of 19 analysts rate it Buy/Strong Buy, mean price target of $151.25 implies 126.5% upside from the current $66.79
sNDA for PIK3CA mutant indication could roughly double the eligible patient population if approved, based on the VIKTORIA-1 mutant cohort data showing 21.5-month median PFS
▼ Bear Case5
Stock has fallen sharply from its pre-approval highs: the FDA approval day saw an 11.8% decline, and the stock has continued to slide from ~$103 in July to $66.79 in November 2026, suggesting a 'sell the news' pattern
No product revenue yet in Q3 2026 (launched Sept 30), with a $73.3 million net loss as the company invests heavily in commercial infrastructure
Competition from alpelisib (Piqray, Novartis) for PIK3CA mutant patients and from other CDK4/6 inhibitor combinations could limit market share
Some institutional exits: Citadel Advisors and Walleye Capital fully exited in Q2 2026; Jefferies and others trimmed significantly in Q3 2026
sNDA for the PIK3CA mutant indication faces regulatory uncertainty and has no confirmed PDUFA date yet, extending the timeline for label expansion

Upcoming Catalysts

  • sNDA decision for PIK3CA mutant label expansion (no confirmed PDUFA date yet; if standard review, ~June 2027; if priority review, ~February 2027)
  • First meaningful quarterly product revenue reporting (Q4 2026 earnings, expected early 2027)
  • Commercial launch metrics and prescription uptake data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Celcuity Inc. 8-K CELC ·Originating report

Sources · 9

Hover a chip for the title
1 webmd.com2 morningstar.com3 cancernetwork.com4 markets.businessinsider.com5 fiercepharma.com6 seekingalpha.com7 markets.businessinsider.com8 taiwannews.com.tw9 sec.gov